Miyatake Satoko, Mitsuhashi Satomi, Hayashi Yukiko K, Purevjav Enkhsaikhan, Nishikawa Atsuko, Koshimizu Eriko, Suzuki Mikiya, Yatabe Kana, Tanaka Yuzo, Ogata Katsuhisa, Kuru Satoshi, Shiina Masaaki, Tsurusaki Yoshinori, Nakashima Mitsuko, Mizuguchi Takeshi, Miyake Noriko, Saitsu Hirotomo, Ogata Kazuhiro, Kawai Mitsuru, Towbin Jeffrey, Nonaka Ikuya, Nishino Ichizo, Matsumoto Naomichi
Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan; Clinical Genetics Department, Yokohama City University Hospital, Yokohama, Kanagawa 236-0004, Japan.
Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan; Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan; Biomedical Informatics Laboratory, Department of Molecular Life Science, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Am J Hum Genet. 2017 Jan 5;100(1):169-178. doi: 10.1016/j.ajhg.2016.11.017. Epub 2016 Dec 22.
Nemaline myopathy (NM) is a common form of congenital nondystrophic skeletal muscle disease characterized by muscular weakness of proximal dominance, hypotonia, and respiratory insufficiency but typically not cardiac dysfunction. Wide variation in severity has been reported. Intranuclear rod myopathy is a subtype of NM in which rod-like bodies are seen in the nucleus, and it often manifests as a severe phenotype. Although ten mutant genes are currently known to be associated with NM, only ACTA1 is associated with intranuclear rod myopathy. In addition, the genetic cause remains unclear in approximately 25%-30% of individuals with NM. We performed whole-exome sequencing on individuals with histologically confirmed but genetically unsolved NM. Our study included individuals with milder, later-onset NM and identified biallelic loss-of-function mutations in myopalladin (MYPN) in four families. Encoded MYPN is a sarcomeric protein exclusively localized in striated muscle in humans. Individuals with identified MYPN mutations in all four of these families have relatively mild, childhood- to adult-onset NM with slowly progressive muscle weakness. Walking difficulties were recognized around their forties. Decreased respiratory function, cardiac involvement, and intranuclear rods in biopsied muscle were observed in two individuals. MYPN was localized at the Z-line in control skeletal muscles but was absent from affected individuals. Homozygous knockin mice with a nonsense mutation in Mypn showed Z-streaming and nemaline-like bodies adjacent to a disorganized Z-line on electron microscopy, recapitulating the disease. Our results suggest that MYPN screening should be considered in individuals with mild NM, especially when cardiac problems or intranuclear rods are present.
杆状体肌病(NM)是一种常见的先天性非营养不良性骨骼肌疾病,其特征为近端优势性肌肉无力、肌张力减退和呼吸功能不全,但通常无心脏功能障碍。据报道,其严重程度差异很大。核内杆状体肌病是NM的一种亚型,在细胞核中可见杆状体,且常表现为严重的表型。虽然目前已知有10个突变基因与NM相关,但只有ACTA1与核内杆状体肌病相关。此外,在约25%-30%的NM患者中,遗传病因仍不清楚。我们对组织学确诊但基因未解决的NM患者进行了全外显子测序。我们的研究纳入了病情较轻、发病较晚的NM患者,并在4个家族中发现了肌 palladin(MYPN)的双等位基因功能丧失突变。编码的MYPN是一种仅定位于人类横纹肌的肌节蛋白。在所有这4个家族中,已鉴定出MYPN突变的个体患有相对较轻的、从儿童期到成年期发病的NM,伴有缓慢进展的肌肉无力。他们在40岁左右出现行走困难。在两名个体中观察到呼吸功能下降、心脏受累以及活检肌肉中的核内杆状体。在对照骨骼肌中,MYPN定位于Z线,但在受影响个体中则缺失。在Mypn中具有无义突变的纯合敲入小鼠在电子显微镜下显示Z线流和与紊乱的Z线相邻的杆状体样结构,重现了该疾病。我们的结果表明,对于轻度NM患者,尤其是存在心脏问题或核内杆状体时,应考虑进行MYPN筛查。